These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 2816859)
21. The importance of high-tone audiometry in monitoring for ototoxicity. Tange RA; Dreschler WA; van der Hulst RJ Arch Otorhinolaryngol; 1985; 242(1):77-81. PubMed ID: 3899068 [TBL] [Abstract][Full Text] [Related]
22. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review. Farzal Z; Kou YF; St John R; Shah GB; Mitchell RB Laryngoscope; 2016 Jan; 126(1):228-35. PubMed ID: 26152803 [TBL] [Abstract][Full Text] [Related]
23. Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients. Gleser MA; Zettner EM Int J Audiol; 2018 Dec; 57(12):917-924. PubMed ID: 30382794 [TBL] [Abstract][Full Text] [Related]
24. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis. Elson EC; Meier E; Oermann CM J Cyst Fibros; 2021 Mar; 20(2):284-287. PubMed ID: 32811788 [TBL] [Abstract][Full Text] [Related]
26. Hearing loss in cystic fibrosis. Martins LM; Camargos PA; Becker HM; Becker CG; GuimarĂ£es RE Int J Pediatr Otorhinolaryngol; 2010 May; 74(5):469-73. PubMed ID: 20189661 [TBL] [Abstract][Full Text] [Related]
27. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407 [TBL] [Abstract][Full Text] [Related]
28. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis. Crifo S; Antonelli M; Gagliardi M; Lucarelli N; Marcolini P Int J Pediatr Otorhinolaryngol; 1980 Sep; 2(3):251-3. PubMed ID: 6821312 [No Abstract] [Full Text] [Related]
29. Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort. Blankenship CM; Hunter LL; Feeney MP; Cox M; Bittinger L; Garinis AC; Lin L; McPhail G; Clancy JP Am J Audiol; 2021 Oct; 30(3S):834-853. PubMed ID: 33465313 [TBL] [Abstract][Full Text] [Related]
30. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Mulheran M; Degg C; Burr S; Morgan DW; Stableforth DE Antimicrob Agents Chemother; 2001 Sep; 45(9):2502-9. PubMed ID: 11502521 [TBL] [Abstract][Full Text] [Related]
31. High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Frank T Ear Hear; 2001 Apr; 22(2):161-8. PubMed ID: 11324845 [TBL] [Abstract][Full Text] [Related]
32. Ototoxicity of aminoglycoside antibiotics in infants and children. Assael BM; Parini R; Rusconi F Pediatr Infect Dis; 1982; 1(5):357-65. PubMed ID: 6760147 [No Abstract] [Full Text] [Related]
33. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Fausti SA; Larson VD; Noffsinger D; Wilson RH; Phillips DS; Fowler CG Ear Hear; 1994 Jun; 15(3):232-9. PubMed ID: 8076721 [TBL] [Abstract][Full Text] [Related]
34. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. O'Donnell EP; Scarsi KK; Scheetz MH; Postelnick MJ; Cullina J; Jain M Int J Antimicrob Agents; 2010 Jul; 36(1):94-5. PubMed ID: 20382508 [No Abstract] [Full Text] [Related]
35. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950 [TBL] [Abstract][Full Text] [Related]
36. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Garinis AC; Cross CP; Srikanth P; Carroll K; Feeney MP; Keefe DH; Hunter LL; Putterman DB; Cohen DM; Gold JA; Steyger PS J Cyst Fibros; 2017 May; 16(3):401-409. PubMed ID: 28238634 [TBL] [Abstract][Full Text] [Related]
37. Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity. Sone M; Schachern PA; Paparella MM Hear Res; 1998 Jan; 115(1-2):217-23. PubMed ID: 9472750 [TBL] [Abstract][Full Text] [Related]
38. Aminoglycoside induced ototoxicity risk in the cystic fibrosis population: The utility of large-scale screening. Lopes J; Vidal-Folch N; Lundquist P; Schimmenti LA; Demirel N; Dean V; Olson J; Auth T; Butz M; Reed K; Wylam M; Balcom J; Boczek NJ; Hasadsri L Pediatr Pulmonol; 2023 Mar; 58(3):819-824. PubMed ID: 36437230 [TBL] [Abstract][Full Text] [Related]
39. Pure tone audiograms and possible aminoglycoside-induced hearing loss in belugas (Delphinapterus leucas). Finneran JJ; Carder DA; Dear R; Belting T; McBain J; Dalton L; Ridgway SH J Acoust Soc Am; 2005 Jun; 117(6):3936-43. PubMed ID: 16018495 [TBL] [Abstract][Full Text] [Related]